Cover Page

Cite item


The aim of the work is to carry out immunogenetic studies of women at risk of developing infectious-associated forms of cervical cancer and to develop immunogenetic criteria for the risk of cervical cancer. Materials and methods of the prospective study - 120 women participated in the study with the obligatory presence of voluntary medical consent in the age range from 19 to 42 years. Processing of biological material (biopsy, scrapings) was carried out using sets of “DNA technology” for human papillomavirus 16.18 types. The program included the study of cytolytic cells in cervical biopsies with phenotype CD3-CD16+CD56+. Normative values for a given pool of cells was defined as comparable in the peripheral blood in the range of 5-9%. Generirovanie pre sekvenirovanie material was performed at clinical Centre absolute. The basic pathologic-and-genetic mechanisms for its implementation and the Association with certain genotypes. As a result of studies, the risk criteria for the development of neoplastic process in women with different degrees of dysplasia infected with human papilloma virus 16/18 type were determined. It was revealed that the number of natural killers associated with genetic markers is a criterion of infection-induced process, including neoplastic. It is shown that the decrease in the activity of cytolytic cells associated with the genotype of human leukocyte antigen HLAV35, with the human papillomavirus 16\18 positive women, compared with groups II and III (human papillomavirus 16\18+), leads to the aggravation of the pathological process and the development of cervical cancer. The number of natural keellers associated with genetic markers is a criterion of infection-induced.

About the authors

E A Levkova

Peoples’ Friendship University of Russia (RUDN University)

Author for correspondence.

Doctor of Medicine, professor, Peoples’ Friendship University of Russia

V A Pushkar

OOO “Immunorehabilitation Center”


O A Grebenya

OOO “Immunorehabilitation Center”


S Z Savin

Federal State Budget Educational Institution of Higher Education “Pacific State University”



  1. Maltseva L.I., Farrokhova L.N., Nyukhnin M.A. Innovative approaches to the diagnosis of precancer and cervical cancer in women with HPV associated cervicitis. Ulyanovsk Medical and Biological Journal, 2013. No. 3. P. 85—88.
  2. Granov A.M., Molchanov O.E. Carcinogenesis and immunobiology of the tumor. Fundamental and clinical aspects. Oncology issues. 2008. No. 4. Vol. 54. P. 401—409.
  3. Kuji S., Hirashima Y., Nakayama H. et al. Diagnosis, clinicopathologic features, treatment, and prognosis of small cell carcinoma of the uterine cervix; Kansai Clinical Oncology Group/Intergroup study in Japan. Gynecol. Oncol. 2013. Vol. 129. P. 522—527.
  4. Orekhova E.K., Khachaturyan A.R. Opportunities for diagnosis of papillomavirus infection: a review: world studies. Journal of Obstetrics and Women’s Diseases. 2014. T. LXII. Issue 3. P. 82—87.
  5. Prevention of cervical cancer. A guide for doctors. Ed. by G.T. Sukhikh, V.N. Prilepskaya. Moscow: MEDPRESS-INFORM, 2012.
  6. Pushkar V.A., Chudnovsky K.V. Pre-cancer and cervical cancer: the possibility of ultrasound diagnosis. Far Eastern Medical Journal. 2015. № 3. P. 85—86.
  7. Rogovskaya S.I. Papillomavirus infection in women and pathology of the cervix. Moscow: GEOTAR-Media: 2008. 234 p.
  8. Urazova L.N., Vidyaeva I.G. Cervical cancer and papilloma viruses: etiopathogenic aspects (review of literature). Siberian Cancer Journal. 2009. No. 1 (31). P. 64—71.
  9. Cohen J.G., Kapp D.S., Shin J.Y. et al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am. J. Obstet. Gynecol. 2010. Vol. 203. P. 3471—3476.
  10. Campbell C.M.P., Menezes L.J., Paskett E.D. & Giuliano A.R. (2012). Prevention of invasive cervical cancer in the United States: past, present, and future. Cancer Epidemiology Biomarkers & Prevention, 21 (9), 1402—1408. doi: 10.1158/1055-9965.
  11. Morkhov K.Yu., Nechushkina V.M., Kuznetsov V.V. Cervical cancer. Clinical Oncology. Ed. by V.P. Kozachenko. Moscow: Binom, 2015. P. 109—177.
  12. Moscicki A.B., Schiffman M., Kjaer S., Villa L.L. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24: S42—51.
  13. Rogovskaya S.I., Bebneva T.N. Tservikalnaya papillomavirusnaya infektsiya. Vozmozhnosti kombinirovannoy terapii [Cervical HPV infection: Possibilities for combined therapy. Akush. i gin. [Obstetrics and gynecology]. 2016. № 11. P. 26—32. [In Russ.].
  14. Lee J.M., Lee K.B., Nam J.H. et al. Prognostic factors in FIGO stage IB—IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann. Oncol. 2008. Vol. 19. P. 321—326.
  15. Apolihina I.A., Filippenkova E.V., Dodova E.G. i dr. Sovremennyie vozmozhnosti organizovannogo skriniga raka sheyki matki [Current possibilities of organized screening for cancer of the cervix uteri]. Akush. i gin. [Obstetrics and gynecology]. 2016. № 9. P. 12—18. [In Russ.].
  16. Bayramova G.R., Fayzullin L.Z., Korolkova A.I. i dr. Skrining raka sheyki matki: chto novogo v mirovoy praktike [Cervical cancer screening: What is new in global practice?]. Akush. i gin. [Obstetrics and gynecology]. 2016. № 7. P. 17—21. [In Russ.].
  17. Stoler M.H., Schiffman M. Interobserver reproducibility of cervical cytology and histologic interpretations. Realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001. Vol. 285. P. 1500—1505.
  18. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S. et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer. 2006. Vol. 119. P. 1095—1101.
  19. Kazachenko V.L. Small cell carcinoma of the cervix. J. obstetrics and gynecology. 2017. No. 1. P. 32—34.
  20. Novik V.I. the Epidemiology of cancer of neck of uterus, risk factors, screening. Pract. oncology. 2002. Vol. 3, No. 3. C. 156—162.

Copyright (c) 2018 Levkova E.A., Pushkar V.A., Grebenya O.A., Savin S.Z.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies